These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Preclinical approaches to the development of effective immunotherapeutic protocols for the treatment of metastasis. Talmadge JE Prog Clin Biol Res; 1986; 212():197-215. PubMed ID: 3520577 [No Abstract] [Full Text] [Related]
23. [A case of Stewart-Treves syndrome--treatment with recombinant interleukin 2 and a review of Japanese literature]. Nabeya R; Kobayashi M; Fujita M; Yorifuji K; Eguchi N; Okamoto S Nihon Hifuka Gakkai Zasshi; 1990 Sep; 100(10):1029-39. PubMed ID: 2266596 [TBL] [Abstract][Full Text] [Related]
24. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545 [TBL] [Abstract][Full Text] [Related]
25. Treatment of kaposiform hemangioendothelioma and tufted angioma. Liu XH; Li JY; Qu XH; Yan WL; Zhang L; Yang C; Zheng JW Int J Cancer; 2016 Oct; 139(7):1658-66. PubMed ID: 27252149 [TBL] [Abstract][Full Text] [Related]
29. Relapse after successful treatment with immunotherapy: lessons for the future. Fisher RI Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407 [No Abstract] [Full Text] [Related]
30. [Spindle-cell hemangioendothelioma with monomelic and multifocal form in a child]. Bodemer C; Fraitag S; Amoric JC; Benaceur S; Brunelle F; De Prost Y Ann Dermatol Venereol; 1997; 124(12):857-60. PubMed ID: 9732761 [TBL] [Abstract][Full Text] [Related]
31. Denileukin diftitox plus total skin electron beam radiation in patients with treatment-refractory cutaneous T-cell Lymphoma (mycosis fungoides): report of four cases. Buder K; Müller PA; Beckmann G; Ugurel S; Bröcker EB; Becker JC Acta Derm Venereol; 2014 Jan; 94(1):94-6. PubMed ID: 23756575 [No Abstract] [Full Text] [Related]
33. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
34. [Recombinant interleukin-2 (roncoleukin) in therapy of the patients with skin melanoma]. Korovin SI; Tolstopiatov BA; Dovgopolaia OA; Palivets AIu Lik Sprava; 2005; (1-2):82-6. PubMed ID: 15916002 [TBL] [Abstract][Full Text] [Related]
35. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Ohguri T; Imada H; Nomoto S; Yahara K; Hisaoka M; Hashimoto H; Tokura Y; Nakamura K; Shioyama Y; Honda H; Terashima H; Moroi Y; Furue M; Korogi Y Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1446-53. PubMed ID: 15817349 [TBL] [Abstract][Full Text] [Related]
36. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Kawa-Ha K; Franco E; Doi S; Yumura K; Ishihara S; Tawa A; Yabuuchi H Lancet; 1987 Jan; 1(8525):154. PubMed ID: 2879982 [No Abstract] [Full Text] [Related]